Lapatinib, a TKI Dual Inhibitor of Her1 and Her2 Receptors: Review of the Literature

Journal of Cancer Therapy
doi 10.4236/jct.2012.36148
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Scientific Research Publishing, Inc,

Related search

Lapatinib, a Dual Inhibitor of ErbB-1/-2 Receptors, Enhances Effects of Combination Chemotherapy in Bladder Cancer Cells

International Journal of Oncology
Cancer ResearchOncology
2009English

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and Is Synergistic With Trastuzumab in Vitro and in Vivo

Clinical Cancer Research
Cancer ResearchOncology
2010English

Preclinical Antitumor Activity of BMS-599626, a Pan-Her Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

Clinical Cancer Research
Cancer ResearchOncology
2006English

HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes From the HER1/EGFR Inhibitor Rash Management Forum

Oncologist
Cancer ResearchMedicineOncology
2005English

Sticky Platelet Syndrome and the Role of Glycoprotein Receptors: A Review of Literature

Journal of Blood Disorders & Transfusion
2013English

Dual-Class Firms: A Comprehensive Literature Review

2017English

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue

PLoS ONE
Multidisciplinary
2013English

Dacomitinib (PF-00299804), an Irreversible Pan-Her Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma

JAMA Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy